1. Home
  2. ELMD vs LYEL Comparison

ELMD vs LYEL Comparison

Compare ELMD & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Electromed Inc.

ELMD

Electromed Inc.

SELL

Current Price

$23.00

Market Cap

204.1M

Sector

Health Care

ML Signal

SELL

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

SELL

Current Price

$13.64

Market Cap

195.8M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
ELMD
LYEL
Founded
1992
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
204.1M
195.8M
IPO Year
2010
2021

Fundamental Metrics

Financial Performance
Metric
ELMD
LYEL
Price
$23.00
$13.64
Analyst Decision
Strong Buy
Buy
Analyst Count
2
8
Target Price
★ $48.50
$37.63
AVG Volume (30 Days)
38.8K
★ 212.6K
Earning Date
11-10-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 52.94
N/A
EPS
★ 0.32
N/A
Revenue
★ $54,716,000.00
$36,000.00
Revenue This Year
$11.55
N/A
Revenue Next Year
$10.94
N/A
P/E Ratio
$72.69
★ N/A
Revenue Growth
★ 13.83
N/A
52 Week Low
$22.67
$7.20
52 Week High
$47.40
$45.00

Technical Indicators

Market Signals
Indicator
ELMD
LYEL
Relative Strength Index (RSI) 27.51 54.63
Support Level $23.03 $12.25
Resistance Level $24.99 $14.97
Average True Range (ATR) 1.24 1.67
MACD -0.29 -0.18
Stochastic Oscillator 8.17 43.74

Price Performance

Historical Comparison
ELMD
LYEL

About ELMD Electromed Inc.

Electromed Inc is a United States-based company that develops, manufactures and markets airway clearance products that apply High Frequency Chest Wall Oscillation (HFCWO) therapy in pulmonary care for patients of all ages. The company markets its products in the U.S. to the homecare and hospital markets. Its product includes the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The company operates in a single segment: developing, manufacturing, and marketing medical equipment. The company generates revenue from Homecare, Hospital, Homecare Distributor, and Other.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: